| Old Articles: <Older 5731-5740 Newer> |
|---|
 |
The Motley Fool
June 29, 2009
Brian Orelli |
Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here.   |
The Motley Fool
June 29, 2009
Brian Orelli |
Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug. |
The Motley Fool
June 29, 2009
Brian Orelli |
Your Company Has Been Raided. What Now? Lately, investors have had to worry about pharmaceutical companies keeping their drugs on the market. |
The Motley Fool
June 26, 2009
Brian Orelli |
Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer. |
The Motley Fool
June 26, 2009
Brian Orelli |
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. |
The Motley Fool
June 26, 2009
Brian Orelli |
Novartis Leads the Pack Biosimilars come to Japan; will the U.S. be next? In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given. |
The Motley Fool
June 26, 2009
Brian Orelli |
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
BusinessWeek
June 25, 2009
Catherine Arnst |
The Family Doctor: A Remedy for Health-Care Costs? How making primary-care physicians the center of America's health-care system could drive down costs. |
The Motley Fool
June 25, 2009
Brian Orelli |
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. |
| <Older 5731-5740 Newer> Return to current articles. |
